<DOC>
	<DOC>NCT00199381</DOC>
	<brief_summary>This is an, open-label, long-term safety extension for patients in North America who have completed the prior istradefylline study 6002-INT-001.</brief_summary>
	<brief_title>An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001</brief_title>
	<detailed_description>Patients with Parkinson's disease with motor complications on levodopa therapy who completed the prior double-blind study 6002-INT-001 are eligible to enter into this long-term open safety study with a starting istradefylline dose of 20 or 40mg per day.</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Istradefylline</mesh_term>
	<criteria>Completion of study 6002INT001 Not of childbearing potential Cancer within 5 years of enrollment ALT/AST levels &gt; 2.5 times ULN</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Parkinson's Disease</keyword>
	<keyword>levodopa</keyword>
	<keyword>end of dose wearing off</keyword>
	<keyword>OFF time</keyword>
</DOC>